Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks

Core Insights - The article discusses the rising interest in GLP-1 and weight loss stocks, highlighting the potential in the obesity market and the performance of key players like Eli Lilly, which became the first trillion-dollar pharmaceutical company last year [1] Industry Overview - The obesity market is recognized as a pandemic, with estimates suggesting over three billion people will be obese globally by 2030, including more than 100 million in the United States [2] - Currently, only about five million people in the U.S. are being served by existing treatments, indicating a significant unmet need in the market [2] Company Performance - Viking Therapeutics Inc. (NASDAQ:VKTX): - Developing a weight loss drug VK-2735 targeting GLP-1 and GIP receptors - Shares are down 0.7% since Cramer's remarks, with a notable drop of 42% in August 2025 after mid-stage trial results showed only a 12% weight loss [6][7] - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): - Focuses on weight loss drugs that help retain lean muscle mass - Shares are up 10.6% since Cramer's remarks, with a year-to-date increase of 16.32% and a quarterly revenue of $3.75 billion, exceeding analyst expectations [8]